Research programme: YSAVA monoclonal antibody - Y's Therapeutics

Drug Profile

Research programme: YSAVA monoclonal antibody - Y's Therapeutics

Alternative Names: AntVec monoclonal antibody series; YSAVA monoclonal antibody research programme - Y's Therapeutics; YSAVA-1L; YSAVA-3L

Latest Information Update: 23 Sep 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ys Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 19 Jul 2005 This programme is still in active development
  • 12 Mar 2004 Preclinical trials in Solid tumours in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top